Relay Medical Corp. (“Relay” or the
“Company”) (CSE: RELA, OTC: RYMDF, Frankfurt:
EIY2) and Fio Corporation (“Fio”) – together through their
joint venture, Fionet Rapid Response Group (“FRR”) – are pleased to
announce an agreement with the global IT solutions company, Unisys
Corporation1
(NYSE: UIS)2, for
jointly marketing a combined solution, that includes FRR’s Fionet
Platform for pandemic and biosecurity management, for the large,
underserved biosecurity market.
FRR’s Fionet Platform for pandemic and
biosecurity management will be integrated with Unisys’
best-in-class U-Pass™3, which digitally authenticates individuals’
health status. This combination of Fionet mobile testing, triage,
and reporting capabilities and U-Pass’ mobile authentication
technologies will both increase and simplify biosecurity management
capability for clients from markets such as large enterprises,
governments, transport and maritime industries.
“Our goal is to create a safer environment for
any public or private organization in any industry looking to bring
employees, guests and students back in large numbers, quickly,”
said Chris Kloes, Vice President, Cybersecurity Solutions,
Unisys Corp. “Together with FRR, we provide an integrated,
secure testing and digital health management solution that can be
scaled to organizations of any size, allowing our clients to gain
better control over who can access their environment.”
The market for COVID-19 diagnostic products and
services is expected to exceed USD $84 billion4. FRR and Unisys
believe they have a well differentiated, end-to-end offering by
combining technologies, marketing, and service and support
capabilities.
“We are very excited to be working with Unisys,
and to continue to grow with other strategic relationships and
industry leaders to collaborate and provide innovative market
solutions. Our expertise in technology and infectious disease
testing has been successful around the world for a variety of use
cases, treating over 1 million patients,” said Yoav Raiter,
CEO Relay Medical Corp. “Unisys has a powerful market
presence in IT solutions and business processes, that we are
excited to begin integrating with as we evaluate the many potential
benefits of joining our technical strengths to achieve market
penetration.”
Unisys is a leading global IT solutions company
that brings technological innovation to businesses and governments
around the world. The company provides state-of-the-art solutions,
such as the U-Pass™ comprehensive COVID-19 testing and health
management solution, which was developed in response to the
coronavirus pandemic. Unisys drives secure, reliable and advanced
industry-leading digital workplace, cloud and infrastructure,
enterprise computing and business processing solutions. Proudly
integrating security into all of its IT and digital offerings,
Unisys delivers a world-class software operating environment.
“This pandemic isn’t a transient event, nor will
life after COVID equal life before COVID. It is a new era for this
whole, interconnected world. In this new era, FRR is in a strong
position to make a great contribution to protecting people,
jurisdictions, and economic activity, and to build its business by
doing that. FRR is making careful alliances with substantial
companies such as Unisys, with massive capabilities to create
large-scale, durable solutions and customer relationships,”
said Dr. Michael Greenberg, CEO FRR.
FRR’s Fionet Platform enables fast, scalable,
quality-controlled testing and real-time automatic digital results
for electronic reporting. Fionet supports frontline testing and
continuously captures and transmits comprehensive data to a
centralized aggregation point. In real-time, the Fionet Portals
allows off-site supervisors to track and direct frontline action,
displaying accurate epidemiological information and providing
actionable insights.
The Company announces that it has granted an aggregate of
500,000 options to purchase common shares of the Company at $0.25
per common share and expiring five (5) years from the date of
grant, to certain officers, directors and consultants of the
Company.
RECENT NEWS: Relay recently
announced a $750,000 Deployment of the Fionet Platform for Malaria
Epidemic Management in Rwanda, Africa: https://bit.ly/2VKkTWQ
In addition, the Company recently announced
other notable testing deployments including the Toronto Tennis
Canada National Bank Open Tournament, qualifying games for FIFA
2021 and the Toronto International Film Festival with Canada’s
largest lab company.
SUBSCRIBE: For more information
on Relay or to subscribe to the Company’s mail list visit:
https://www.relaymedical.com/news
About Unisys
Unisys (NYSE:UIS) is a global IT solutions
company that delivers successful outcomes for the most demanding
businesses and governments. Unisys offerings include digital
workplace solutions, cloud and infrastructure solutions, enterprise
computing solutions, business process solutions and cybersecurity
solutions. For more information on how Unisys delivers for its
clients across the commercial, financial services and government
markets.
Website: www.unisys.com
About Fionet
The Fionet Platform is an end-to-end, rapid
testing and tracking solution for community-based or decentralized
settings. Combining a fast, handheld point-of-need device connected
in real time to cloud data services, the Fionet Platform handles
scheduling and registration via phone app for at home, on-site
check-in and rapid on-the-spot universal antigen testing. The
platform allows for data integration with other testing methods and
devices, providing result notification for patient and public
health authorities as appropriate, and anonymized data and
statistics for dashboards for authorized stakeholders.
Recent overview and walkthrough video of Fionet Testing
Platform:https://www.youtube.com/watch?v=pzH6Yy33Qq0&t=3s
Website: www.fionetrapidresponse.com
About Relay Medical Corp.
Relay Medical is a technology innovator
headquartered in Toronto, Canada focused on the development of
novel solutions in the diagnostics, AI data science and IoT
security sectors. Relay recently acquired Cybeats Technologies, a
platform which offers a holistic approach to cybersecurity and
addresses the $73 billion IoT security market through their
Software Bill of Materials and microagent solution. Cybeats
provides real-time cybersecurity for connected devices, critical
infrastructure, automotive, medical and IoT (Internet of Things)
sectors.
The Company is holding a Special Meeting to
approve a Name Change on September 20, 2021 as the Company’s core
competencies and product offerings have organically grown beyond
the medical device industry, and this expansion into new industries
and businesses will be reflected in the Name Change. The Company’s
new name will more aptly and effectively communicate the business
and its commercial verticals.
Website: www.relaymedical.com
Contact:Destine LeeMedia &
CommunicationsRelay Medical Corp.Office. 647-872-9982TF.
1-844-247-6633Media Inquiries: media@relaymedical.com Investor
Relations: investor.relations@relaymedical.com
Forward-looking Information Cautionary
StatementExcept for statements of historic fact, this news
release contains certain "forward-looking information" within the
meaning of applicable securities law. Forward-looking information
is frequently characterized by words such as "plan", "expect",
"project", "intend", "believe", "anticipate", "estimate" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements are based on the
opinions and estimates at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors
that could cause actual events or results to differ materially from
those anticipated in the forward-looking statements including, but
not limited to delays or uncertainties with regulatory approvals,
including that of the CSE. There are uncertainties inherent in
forward-looking information, including factors beyond the Company’s
control. There are no assurances that the commercialization plans
for the technology described in this news release will come into
effect on the terms or time frame described herein. The Company
undertakes no obligation to update forward-looking information if
circumstances or management's estimates or opinions should change
except as required by law. The reader is cautioned not to place
undue reliance on forward-looking statements. Additional
information identifying risks and uncertainties that could affect
financial results is contained in the Company’s filings with
Canadian securities regulators, which filings are available at
www.sedar.com
1 http://www.unisys.com2 https://www.nyse.com/quote/XNYS:UIS3
https://www.unisys.com/solutions/cloud-and-infrastructure-solutions/u-pass/4
https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market
Unisys (NYSE:UIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Unisys (NYSE:UIS)
Historical Stock Chart
From Apr 2023 to Apr 2024